Purpose: Lymphocytic bronchiolitis (LB) is the strongest risk factor for subsequent allograft loss due to obliterative bronchiolitis (OB), however it is poorly assessed by transbronchial biopsy (TBBx) because of sampling error, interpretation error, and the presence of non-alloreactive airway inflammation. We hypothesised that flow cytometric interrogation of small airway brushings -the 'B score' may be a better tool. Methods and Materials: 43 small airway brushings (2-3 cm from pleural surface, 2mm OD Olympus cytology brush) were obtained under radiologic guidance prior to TBBx from 28 patients (16 female, median age 41 (23-64), 14 CF, 7 COPD), and labelled with conjugated antibodies to epithelial cell antigen, CD3 and CD103 (an integrin which binds to the epithelial specific ligand e-cadherin) before undergoing flow cytometry. The B score was defined as the % of total nucleated cells which were CD3 ϩ CD103 ϩ . Results: No adverse events occurred. The mean B score was 0.71% (95% CI 0.47-0.96) and was higher in patients with A1 rejection (1.39% vs A0 0.53%, pϽ0.001), but was unrelated to B grade (B0 1.1%, B1 0.6%, B2 0.94%, Bx 0.78%, pϭNS) or A2 (nϭ2) rejection. Total CD3 ϩ cell counts were higher in B1/2 (2.16%) or Bx (2.18%) vs B0 biopsies (1.14%, pϭ0.01), however most cells were CD103 Ϫ suggesting that they were not alloreactive. Viral (Parainfluenza 2, CMV 1, Influenza B 1) or invasive fungal (Aspergillus 3, Acremonium 1) infection was associated with marked infiltration with CD3 ϩ CD103 Ϫ cells (no infection 0.46%, bacterial 0.39%, viral 2.08% (pϽ0.01), fungal 2.06% (pϽ0.01)). The B score was above the upper 95% CI in 9 (21%) cases (3 prior to or at the onset of refractory OB; 2 with unexplained (TBBx negative, infection negative) steroid responsive fall in FEV1; 2 stable OB; 1 Parainfluenza; 1 gastrooesophageal reflux). Conclusions: Flow cytometric interrogation of small airway brushings can accurately discriminate between infective and alloreactive LB. The B score is simple to obtain, low risk and may be a valuable addition to current lung allograft assessment.